C. Rhee (Seoul, Republic of Korea), C. Gotera Rivera (Madrid, Spain)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Cross-sectional study on therapeutic adherence and disease knowledge of patients affected by chronic obstructive pulmonary disease.
M. Fekete (Budapest, Hungary), V. Fazekas-Pongor (Budapest, Hungary), G. Szollosi (Debrecen, Hungary), M. Kerti (Budapest, Hungary), J. Varga (Budapest, Hungary)
|   |
Sugar coating hypoxia – Metformin risks?
D. Barber (Liverpool, United Kingdom), C. Barber (Middlewich, United Kingdom), D. Wat (Liverpool, United Kingdom), N. Glover (Liverpool, United Kingdom)
| |
Influence of government-driven quality assessment program on patients with chronic obstructive pulmonary disease
H. Park (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), H. Lee (Seoul, Republic of Korea), B. Kim (Seoul, Republic of Korea), H. Kim (Seoul, Republic of Korea), S. Ahn (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), J. Park (Seoul, Republic of Korea)
| |
Effect of physical position on peak inspiratory flow in stable COPD
M. Drummond (Chapel Hill, United States of America), A. Henderson (Chapel Hill, United States of America), A. Shaikh (Ridgefield, United States of America), V. Bayer (Ridgefield, United States of America), R. Pleasants (Chapel Hill, United States of America)
| |
Endobronchial valve lung volume reduction and small airways function
J. Garner (London, United Kingdom), M. Biddiscombe (London, United Kingdom), S. Meah (London, United Kingdom), A. Lewis (London, United Kingdom), S. Buttery (London, United Kingdom), N. Hopkinson (London, United Kingdom), S. Kemp (London, United Kingdom), O. Usmani (London, United Kingdom), P. Shah (London, United Kingdom), S. Verbanck (London, United Kingdom)
| |
Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
I. Schouten (Leiden, Netherlands), M. Kasteleyn (Leiden, Netherlands), R. Bals (Homburg/Saar, Germany), A. Turner (Birmingham, United Kingdom), I. Ferrarotti (Pavia, Italy), A. Corsico (Pavia, Italy), B. Lara Gallego (Coventry, United Kingdom), M. Miravitlles (Barcelona, Spain), R. Stockley (Birmingham, United Kingdom), J. Stolk (Leiden, Netherlands)
| |
Baseline characteristics of patients enrolled in the EARCO prospective registry of alpha-1 antitrypsin deficiency: preliminary results.
A. Turner (Birmingham, United Kingdom), M. Torres (Vigo, Spain), J. López-Campos (Sevilla, Spain), C. Guimaraes (Guimaraes, Portugal), J. Chorostowska-Wynimko (Warsaw, Poland), R. Bals (Homburg, Germany), I. Ferrarotti (Pavia, Italy), G. Mcelvaney (Dublin, Ireland), K. O'Hara (Coventry, United Kingdom), J. Stolk (Leiden, Netherlands), R. Stockley (Birmingham, United Kingdom), M. Wilkens (Berlin, Germany), C. Clarenbach (Zurich, Switzerland), T. Greulich (Marburg, Germany), M. Miravitlles (Barcelona (CT), Spain)
| |
Impact of COVID-19 on treatments’ dispensations for chronic airways diseases in France
A. Bourdin (Montpellier Cedex 5, France), M. Maravic (Paris, France), L. Perray (Courbevoie, France), N. Roche (Paris, France)
| |
Treatment with inhaled corticosteroids in COPD groups GOLD A and B –relationship to clinical state in the COSYCONET cohort
K. Kahnert (Munich, Germany), R. Jörres (Munich, Germany), F. Trudzinski (Heidelberg, Germany), P. Alter (Marburg, Germany), C. Kellerer (Munich, Germany), H. Watz (grosshansdorf, Germany), T. Welte (Hannover, Germany), R. Bals (Homburg, Germany), D. Kauffmann-Guerrero (Munich, Germany), J. Behr (Munich, Germany), R. Holle (Munich, Germany), C. Vogelmeier (Munich, Germany), J. Lutter (Munich, Germany)
| |
Efficacy perception and prescription of treatments for refractory/unexplained chronic cough by Spanish physicians
L. Puente-Maestu (Madrid, Spain), J. Molina-París (Madrid, Spain), J. Trigueros (Toledo, Spain), J. Gómez-Sáenz (La Rioja, Spain), S. Fernandez (Madrid, Spain), M. Sánchez-Jareño (Madrid, Spain), L. Cea-Calvo (Madrid, Spain), J. Domínguez-Ortega (Madrid, Spain)
| |
Association between COPD exacerbations and acute cardiovascular events: a systematic literature review
H. Müllerová (Cambridge, United Kingdom), J. Marshall (Cambridge, United Kingdom), E. De Nigris (Cambridge, United Kingdom), P. Varghese (Gaithersburg, MD, United States of America), N. Pooley (Newcastle upon Tyne, United Kingdom), N. Embleton (Newcastle upon Tyne, United Kingdom), Z. Marjenberg (Newcastle upon Tyne, United Kingdom)
| |
Effect of nocturnal oxygen therapy on daytime pulmonary hemodynamics in patients with COPD travelling to altitude. RCT.
M. Lichtblau (Zürich, Switzerland), T. Latshang (Zürich, Switzerland), S. Aeschbacher (Zürich, Switzerland), F. Huber (Zürich, Switzerland), P. Schweiwiller (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), E. Hasler (Zürich, Switzerland), M. Furian (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Superior laryngeal nerve block in chronic refractory cough
C. Wright (Cottingham, United Kingdom), K. Brindle (Cottingham, United Kingdom), R. Thompson (Cottingham, United Kingdom), A. Morice (Cottingham, United Kingdom)
| |